Abstract:Abstract Background The prevalence of programmed death-ligand 1 (PD-L1) and PD-L2 expression on tumor cells and tumor-infiltrating immune cells in primary central nervous system lymphoma (PCNSL) remains unclear. In the present study, we analyzed needle biopsy and craniotomy specimens of patients with PCNSL to compare the PD-L1 and PD-L2 levels in the tumor and surrounding (peritumoral) tissue. We also assessed the correlation between biological factors and the prognostic significance of PD-L1 and PD-L2 expression. Methods We retrospectively analyzed the cases of 70 patients histologically diagnosed with PCNSL (diffuse large B-cell lymphoma). Immunohistochemistry for CD20, CD68, PD-L1, and PD-L2 was performed. In cases with specimens taken by craniotomy, the percentages of PD-L1- and PD-L2-positive macrophages were evaluated in both tumor and peritumoral tissue. The Kaplan-Meier method with log-rank test and Cox proportional hazard model were used for survival analysis. Results The tumor cells expressed little or no PD-L1 and PD-L2, but macrophages expressed PD-L1 and PD-L2 in most of the patients. The median percentage of PD-L2-positive cells was significantly higher among peritumoral macrophages (32.5%; 95% CI: 0–94.6) than intratumoral macrophages (27.5%; 95% CI: 0–81.1, p = 0.0014). There was a significant correlation between the percentages of PD-L2-positive intratumoral macrophages and PD-L2-positive peritumoral macrophages ( p = 0.0429), with very low coefficient correlation (ρ = 0.098535). PD-L1 expression on macrophages was significantly associated with biological factors (intratumoral macrophages: better KPS, p = 0.0008; better MSKCC score, p = 0.0103; peritumoral macrophages: low proportion of LDH elevation, p = 0.0064) and longer OS (for intratumoral macrophages: high PD-L1 = 60 months, 95% CI = 30–132.6; low PD-L1 = 24 months, 95% CI = 11–48; p = 0.032; for peritumoral macrophages: high PD-L1 = 60 months, 95% CI = 30.7–NR; low PD-L1 = 14 months, 95% CI = 3–26). PD-L1 expression on peritumoral macrophages was strongly predictive of a favorable outcome (HR = 0.30, 95% CI = 0.12–0.77, p = 0.0129). Conclusions Macrophages in intratumoral and peritumoral tissue expressed PD-L1 and PD-L2 at a higher rate than tumor cells. PD-L1 expression, especially on peritumoral macrophages, seems to be an important prognostic factor in PCNSL. Future comprehensive analysis of checkpoint molecules in the tumor microenvironment, including the peritumoral tissue, is warranted.

Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma

Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma

Data from Clinical Implications of Phosphorylated STAT3 Expression in <i>de Novo</i> Diffuse Large B-cell Lymphoma

Clinical significance and prognostic value of STAT 3 expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy

Clinicopathologic Significance of MYD88 L265P Mutation and Expression of TLR4 and P-STAT3 in Primary Central Nervous System Diffuse Large B-cell Lymphomas

Tmic-08. Patterns Of Pstat3 Expression In Reactive Astrocytes Of Brain Metastases From Non-Small Cell Lung Cancer And Correlations With Outcome

STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas

Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?

Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers

The PI3K/AKT/mTOR Signaling Pathway is Aberrantly Activated in Primary Central Nervous System Lymphoma and Correlated with a Poor Prognosis

Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas

Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK- ALCL vs. CD30high PTCL, NOS

Prognostic impact of peripheral natural killer cells in primary central nervous system lymphoma

STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model

Primary Central Nervous System Lymphoma Tumor Biopsies Show Heterogeneity in Gene Expression Profiles, Genetic Subtypes, and in vitro Drug Sensitivity to Kinase Inhibitors

The genomic and transcriptional landscape of primary central nervous system lymphoma

New genetic prognostic biomarkers in primary central nervous system lymphoma (PCNSL)

PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma

Prognostic Significance of STAT3 Expression and Its Correlation with Chemoresistance of Non-Small Cell Lung Cancer Cells

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

STAT3 Mutation Is Associated with STAT3 Activation in CD30+ ALK− ALCL